UBS AM
NAVB

UBS AM’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

UBS AM’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,980
Closed -$79K – 2639
2014
Q3 		$79K Hold
2,980
– – ﹤0.01% 2532
2014
Q2 		$88K Hold
2,980
– – ﹤0.01% 2536
2014
Q1 		$110K Hold
2,980
– – ﹤0.01% 2535
2013
Q4 		$123K Hold
2,980
– – ﹤0.01% 2482
2013
Q3 		$158K Buy
2,980
+250
+9% +$14.6K ﹤0.01% 2396
2013
Q2 		$146K Buy
+2,730
New +$136K ﹤0.01% 2344

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS AM's NAVB Position: Q4 2014 in Review

UBS AM sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2014, closing a stake of 2,980 shares — an estimated $79K sold.

UBS AM first reported a position in NAVB in Q2 2013 and held it in 6 quarters. The position peaked at $158K in Q3 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q4 2014.

  • UBS AM reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2014 after selling out during the quarter.
  • UBS AM sold 2,980 Navidea Biopharmaceuticals Inc. shares in Q4 2014, an estimated $79K.
  • UBS AM first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 6 quarters.
  • UBS AM's Navidea Biopharmaceuticals Inc. position peaked at $158K in Q3 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2014.

Based on UBS AM's 13F filing for Q4 2014, filed 2 Feb 2015.